A Phase 3 interventional study of Bevacizumab and Oxaliplatin in Metastatic Colorectal Cancer, sponsored by US Oncology Research. Completed at 82 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 35th largest by enrollment of the 183 interventional ones that give a count, is one of 15 that started in 2005, is one of 36 in phase 3, and was the 64th registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–70
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 40 · Phase 4 5
First in 1998; this study’s year is marked. 15 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 50 across the 183 interventional studies. Of the 134 that completed or were terminated, 35 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 206 have an industry lead sponsor. The 10 most frequent:
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
Sarah Cannon Research Institute has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing oxaliplatin in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233850Shenyang Sunshine Pharmaceutical Co., LTD.A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
This is a Phase III, open label, nonblinded study. A total of 240 eligible patients will be randomized on a 1:1 basis to either treatment Arm.
In this trial, we will compare the efficacy, safety, and tolerability of this novel combination of biweekly infusional 5-FU/leucovorin plus cetuximab and bevacizumab (FOLF-CB) to the current standard of care, biweekly infusional 5-FU/leucovorin plus oxaliplatin and bevacizumab (Bev-FOLFOX). For practical purposes, this study will be a head to head comparison of oxaliplatin versus cetuximab, since the other components of both regimens will be the same.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle
Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil
(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU. Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU
Drug: Bevacizumab · Drug: Leucovorin · Drug: Fluorouracil · Drug: Cetuximab
5 mg/kg over 30 minutes on Days 1 and 15
Also known as: Avastin
85 mg/m2 on Days 1 and 15
Also known as: Eloxatin
400 mg/m2 on Days 1 and 15
400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
Also known as: 5FU
400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
Also known as: Erbitux
Progression-Free Survival (PFS)
From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring). Kaplan-Meier median PFS time and PFS rate (at 12 months)
Time frame: 12 months
Progression-free Survival (PFS) Rate at 1 Year.
From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).
Time frame: 12 months
Overall Survival (OS)
From randomization to death (event); or last follow-up date if alive (censoring). Kaplan-Meier OS median time.
Time frame: up to 4 years
Objective Response Rate
Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all "per-protocol population" patients.
Time frame: 12 months
A total of 247 patients were recruited from multiple research sites and were randomly assigned to either Arm A or Arm B between December 2005 to June 2007.
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 124 | 123 |
| Completed | 85 | 79 |
| Not completed | 39 | 44 |
| Withdrew: Adverse event | 17 | 13 |
| Withdrew: Unrelated complication | 2 | 1 |
| Withdrew: Disease progression | 14 | 20 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Patient request | 4 | 5 |
| Withdrew: Withdrawal by subject | 0 | 2 |
From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring). Kaplan-Meier median PFS time and PFS rate (at 12 months)
| months | Arm A | Arm B |
|---|---|---|
| Progression-Free Survival (PFS) | 11.0 (9.2 to 13.6) | 8.3 (6.7 to 9.7) |
From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).
| proportion of participants w/ PFS at 1yr | Arm A | Arm B |
|---|---|---|
| Progression-free Survival (PFS) Rate at 1 Year. | 0.45 (0.34 to 0.55) | 0.32 (0.23 to 0.42) |
From randomization to death (event); or last follow-up date if alive (censoring). Kaplan-Meier OS median time.
| Months | Arm A | Arm B |
|---|---|---|
| Overall Survival (OS) | 21.3 (18.2 to 25.2) | 19.5 (16.5 to 21.6) |
Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all "per-protocol population" patients.
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Objective Response Rate | 52.1 (42.7 to 61.5) | 41.2 (32.2 to 50.6) |
Collected over during the whole treatment period, up to 30 days following last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | — | 40/118 (33.9%) | 117/118 (99.2%) |
| Arm B | — | 49/121 (40.5%) | 120/121 (99.2%) |
| Event | Arm A | Arm B |
|---|---|---|
| DEHYDRATIONGastrointestinal disorders | 3/118 | 7/121 |
| THROMBOSISVascular disorders | 4/118 | 7/121 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 2/118 | 4/121 |
| SEPSISInfections and infestations | 1/118 | 4/121 |
| BOWEL OBSTRUCTIONGastrointestinal disorders | 3/118 | 1/121 |
| DIARRHEAGastrointestinal disorders | 3/118 | 3/121 |
| FEBRILE NEUTROPENIAInfections and infestations | 3/118 | 0/121 |
| ABDOMINAL PAINGastrointestinal disorders | 0/118 | 3/121 |
| CHEST PAINRespiratory, thoracic and mediastinal disorders | 0/118 | 3/121 |
| PNEUMONIARespiratory, thoracic and mediastinal disorders | 0/118 | 3/121 |
| Event | Arm A | Arm B |
|---|---|---|
| RASHSkin and subcutaneous tissue disorders | 17/118 | 83/121 |
| NEUROPATHYNervous system disorders | 68/118 | 14/121 |
| NAUSEAGastrointestinal disorders | 59/118 | 54/121 |
| FATIGUEGeneral disorders | 55/118 | 40/121 |
| DIARRHEAGastrointestinal disorders | 53/118 | 50/121 |
| NEUTROPENIABlood and lymphatic system disorders | 49/118 | 19/121 |
| ANEMIABlood and lymphatic system disorders | 45/118 | 28/121 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 42/118 | 22/121 |
| LEUKOPENIABlood and lymphatic system disorders | 37/118 | 26/121 |
| CONSTIPATIONGastrointestinal disorders | 30/118 | 36/121 |
| Age, Categorical(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 73 | 67 | 140 |
| >=65 years | 51 | 56 | 107 |
| Age, Continuous(years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 61 ± 12 | 63 ± 11 | 62 ± 12 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 54 | 50 | 104 |
| Male | 70 | 73 | 143 |
| Race (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 15 | 30 |
| White | 100 | 99 | 199 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 6 | 10 |
| Region of Enrollment(participants) | Arm A | Arm B | Total |
|---|---|---|---|
| United States | 124 | 123 | 247 |
The record gives a start of Sep 2005, a primary completion of Jun 2007 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxaliplatin · Cetuximab